about
The signaling role of CD40 ligand in platelet biology and in platelet component transfusionTransfusion as an Inflammation Hit: Knowns and UnknownsGenetic basis of cystinosis in Tunisian patients: Identification of novel mutation in CTNS gene.Levels of human platelet-derived soluble CD40 ligand depend on haplotypes of CD40LG-CD40-ITGA2Are polymorphisms of the immunoregulatory factor CD40LG implicated in acute transfusion reactions?Development of a highly resolutive method, using a double quadruplex tetra-primer-ARMS-PCR coupled with capillary electrophoresis to study CD40LG polymorphisms.Leucocyte cytokines dominate platelet cytokines overtime in non-leucoreduced platelet components.Platelet components associated with adverse reactions: predictive value of mitochondrial DNA relative to biological response modifiers.The Non-Hemostatic Aspects of Transfused Platelets.Soluble CD40L and CD62P levels differ in single-donor apheresis platelet concentrates and buffy coat-derived pooled platelet concentratesMolecular genetic diagnosis of Tunisian Glanzmann thrombasthenia patients reveals a common nonsense mutation in the ITGA2B gene that seems to be specific for the studied populationTransfusion-associated hazards: A revisit of their presentationDysregulated pathways and differentially expressed proteins associated with adverse transfusion reactions in different types of platelet componentsAssessment of soluble platelet CD40L and CD62P during the preparation process and the storage of apheresis platelet concentrates: Absence of factors related to donors and donationsDifferential protein expression of blood platelet components associated with adverse transfusion reactionsData from differentially expressed proteins in platelet components associated with adverse transfusion reactionsXq28 copy number gain causing moyamoya disease and a novel moyamoya syndromeClinical and Molecular Features of 5 European Multigenerational Families With Moyamoya Angiopathy
P50
Q26863134-3F88CFA2-A85F-4AC1-81A2-BE417B36AAC2Q28074933-7DC518E8-355D-484C-A0FD-C4DB5623CAD4Q35925561-5127E6AB-68D5-4D0D-AD80-2A14F311E66CQ36814919-63E56064-4841-4F68-8164-3C83CE2E60B7Q37741117-6FFF1208-EFBB-405F-A0DC-5C4D6F2002FBQ38870673-E0067CE6-A599-4BE7-BC49-B3A7CF05EA7CQ49443114-2B011320-0AAF-431F-9FBA-38391C31F49DQ50797044-7CF32668-E8C3-47EC-83D7-98EE14317077Q54941751-ECF9CCF5-A41C-480F-B5FA-63CF2CC4D4B8Q57020773-13FDA432-42A8-44B5-BE1A-C515B2C65D37Q57470269-494D993A-9757-45FB-ACE4-0B3CF8AF0234Q88294142-A9A6BFE4-A37D-4176-853D-6931D8AD2910Q89844428-6035119D-CDCC-467B-97A4-B5F026B72B76Q90392210-F1C94A2A-8068-4292-BB7C-0D262F44856CQ90777410-C8BF14F0-96A7-4C9E-A170-2AA32541D8A1Q91813997-9022B188-F1E5-4763-AE09-2A52481313ECQ92562848-FAB84E80-C735-4BF6-91DC-D91CFA1A3179Q92596400-A4C47BED-8E89-4929-B5C2-87511F94EC0C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Chaker Aloui
@ast
Chaker Aloui
@en
Chaker Aloui
@es
Chaker Aloui
@nl
type
label
Chaker Aloui
@ast
Chaker Aloui
@en
Chaker Aloui
@es
Chaker Aloui
@nl
prefLabel
Chaker Aloui
@ast
Chaker Aloui
@en
Chaker Aloui
@es
Chaker Aloui
@nl
P106
P31
P496
0000-0002-0914-5260